Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer
16483
post-template-default,single,single-post,postid-16483,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

Talazoparib and Avelumab for Mismatch Repair Proficient Endometrial Cancer

In patients with recurrent mismatch repair proficient (MMRP) Endometrial Cancer, treatment with talazoparib and avelumab showed 11.4 % confirmed ORR and 22.9 % PFS at 6 months. Patients with homologous recombination repair (HRR) alterations and/or a platinum-free interval (PFI) of ≥6 months were more likely to derive clinical benefit compared with non–HRR-altered tumors and/or PFI ≤6 months and exhibited better PFS.                          (Ref: Konstantinopoulos PA et al. JAMA Oncol. July 28, 2022.)

#oncologyresearch #clinicaldevelopment #cancerresearch

https://www.linkedin.com/feed/update/urn:li:activity:6964212547470155777

No Comments

Sorry, the comment form is closed at this time.